US EditionExperimental Moderna Flu Shot More Effective than Approved Vaccine, Company Says
- Moderna announced on June 30, 2025, that its seasonal flu vaccine candidate mRNA-1010 showed superior efficacy in adults aged 50 and older across 11 countries.
- This Phase 3 trial followed over 40,000 adults randomly assigned to receive mRNA-1010 or a standard licensed flu vaccine during a flu season marked by 15-year-high hospitalizations.
- The vaccine reduced influenza-like illness risk by 26.6% overall, including a 27.4% reduction in those 65 and older, with consistent effectiveness across age groups and flu strains.
- Moderna observed mostly mild side effects, primarily localized discomfort at the injection site and common systemic symptoms such as fatigue and headache, with a safety profile consistent with previous Phase 3 trial findings.
- Following these results, Moderna intends to begin discussions with regulatory authorities to submit approval requests and anticipates that obtaining authorization could allow the introduction of the first mRNA-based flu vaccine in the United States.
17 Articles
17 Articles
Moderna says flu shot more effective than rival GSK in late-stage study
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK in adults aged 50 years and older in a late-stage study, sending its shares up more than 2%.
Moderna to Ask for Clearance for Combination COVID-Influenza Vaccine
Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30. The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness. In the trial, which featured 40,805 participants and compared mRNA-1010 to an existing seasonal flu vaccine i…
Moderna to Ask for Clearance for Combination COVID-Influenza Vaccine - The Thinking Conservative
Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30. The post Moderna to Ask for Clearance for Combination COVID-Influenza Vaccine appeared first on The Thinking Conservative.
Coverage Details
Bias Distribution
- 63% of the sources are Center
To view factuality data please Upgrade to Premium
